229 related articles for article (PubMed ID: 36634146)
21. Nonsynonymous mutations in VEGF receptor binding domain alter the efficacy of bevacizumab treatment.
Ahamed A; Samanta A; Alam SSM; Mir SA; Jamil Z; Ali S; Hoque M
J Cell Biochem; 2024 Feb; 125(2):e30515. PubMed ID: 38213080
[TBL] [Abstract][Full Text] [Related]
22. Role of IL-8 induced angiogenesis in uveal melanoma.
Lattanzio L; Tonissi F; Torta I; Gianello L; Russi E; Milano G; Merlano M; Lo Nigro C
Invest New Drugs; 2013 Oct; 31(5):1107-14. PubMed ID: 23912257
[TBL] [Abstract][Full Text] [Related]
23. Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic.
Gao F; Yang C
Curr Cancer Drug Targets; 2020; 20(1):3-18. PubMed ID: 31729943
[TBL] [Abstract][Full Text] [Related]
24. VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells.
Doi Y; Yashiro M; Yamada N; Amano R; Noda S; Hirakawa K
Ann Surg Oncol; 2012 Aug; 19(8):2733-43. PubMed ID: 22207048
[TBL] [Abstract][Full Text] [Related]
25. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
26. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer.
Terme M; Pernot S; Marcheteau E; Sandoval F; Benhamouda N; Colussi O; Dubreuil O; Carpentier AF; Tartour E; Taieb J
Cancer Res; 2013 Jan; 73(2):539-49. PubMed ID: 23108136
[TBL] [Abstract][Full Text] [Related]
27. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
[TBL] [Abstract][Full Text] [Related]
28. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
[TBL] [Abstract][Full Text] [Related]
29. Aflibercept, bevacizumab and ranibizumab prevent glucose-induced damage in human retinal pericytes in vitro, through a PLA2/COX-2/VEGF-A pathway.
Giurdanella G; Anfuso CD; Olivieri M; Lupo G; Caporarello N; Eandi CM; Drago F; Bucolo C; Salomone S
Biochem Pharmacol; 2015 Aug; 96(3):278-87. PubMed ID: 26056075
[TBL] [Abstract][Full Text] [Related]
30. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Wagner AD; Thomssen C; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.
Corrie PG; Marshall A; Dunn JA; Middleton MR; Nathan PD; Gore M; Davidson N; Nicholson S; Kelly CG; Marples M; Danson SJ; Marshall E; Houston SJ; Board RE; Waterston AM; Nobes JP; Harries M; Kumar S; Young G; Lorigan P
Lancet Oncol; 2014 May; 15(6):620-30. PubMed ID: 24745696
[TBL] [Abstract][Full Text] [Related]
32. VEGF-Independent Angiogenic Factors: Beyond VEGF/VEGFR2 Signaling.
Eguchi R; Kawabe JI; Wakabayashi I
J Vasc Res; 2022; 59(2):78-89. PubMed ID: 35152220
[TBL] [Abstract][Full Text] [Related]
33. Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.
Del Vecchio M; Mortarini R; Canova S; Di Guardo L; Pimpinelli N; Sertoli MR; Bedognetti D; Queirolo P; Morosini P; Perrone T; Bajetta E; Anichini A
Clin Cancer Res; 2010 Dec; 16(23):5862-72. PubMed ID: 21030496
[TBL] [Abstract][Full Text] [Related]
34. Vaccination against galectin-1 promotes cytotoxic T-cell infiltration in melanoma and reduces tumor burden.
Femel J; van Hooren L; Herre M; Cedervall J; Saupe F; Huijbers EJM; Verboogen DRJ; Reichel M; Thijssen VL; Griffioen AW; Hellman L; Dimberg A; Olsson AK
Cancer Immunol Immunother; 2022 Aug; 71(8):2029-2040. PubMed ID: 35018481
[TBL] [Abstract][Full Text] [Related]
35. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2.
Zhang Z; Neiva KG; Lingen MW; Ellis LM; Nör JE
Cell Death Differ; 2010 Mar; 17(3):499-512. PubMed ID: 19834490
[TBL] [Abstract][Full Text] [Related]
36. Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study.
Sudaka A; Susini A; Lo Nigro C; Fischel JL; Toussan N; Formento P; Tonissi F; Lattanzio L; Russi E; Etienne-Grimaldi MC; Merlano M; Milano G
Invest New Drugs; 2013 Feb; 31(1):59-65. PubMed ID: 22714791
[TBL] [Abstract][Full Text] [Related]
37. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
38. Biomarkers for antitumor activity of bevacizumab in gastric cancer models.
Yamashita-Kashima Y; Fujimoto-Ouchi K; Yorozu K; Kurasawa M; Yanagisawa M; Yasuno H; Mori K
BMC Cancer; 2012 Jan; 12():37. PubMed ID: 22273502
[TBL] [Abstract][Full Text] [Related]
39. Effects of bevacizumab on the neovascular membrane of proliferative diabetic retinopathy: reduction of endothelial cells and expressions of VEGF and HIF-1α.
Han XX; Guo CM; Li Y; Hui YN
Mol Vis; 2012; 18():1-9. PubMed ID: 22232563
[TBL] [Abstract][Full Text] [Related]
40. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
